Corcept Therapeutics Incorporated share price logo

Corcept Therapeutics Incorporated

NASDAQ: CORT

Mid Cap

$51.17

-0.03

(-0.05%)

as on

Corcept Therapeutics Incorporated Stock Performance

as on May 13, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $50.60
    $51.48
    downward going graph

    1.11%

    Downside

    0.61%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $28.66
    $91.00
    downward going graph

    43.99%

    Downside

    77.84%

    Upside

    downward going graph

Corcept Therapeutics Incorporated share price movements today

Previous Close
$51.20
Open
$51.15
Volume
586.0K
Day's Low - High
$50.60 - $51.48
52 Week Low - High
$28.66 - $91.00

Corcept Therapeutics Incorporated Historical Returns

1 Month Return
+ 22.17 %
3 Month Return
+ 33.54 %
1 Year Return
-29.03 %
3 Year Return
+ 116.58 %
5 Year Return
+ 148.42 %

Corcept Therapeutics Incorporated Stock Fundamentals & Key Indicators

Check Corcept Therapeutics Incorporated market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$5.5B

EPS (TTM)

0.4775

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.22%

PE Ratio (TTM)

146.29

Industry PE ratio

-9.908

PEG Ratio

0.813

EBITDA

-6.9M

Revenue (TTM)

769.1M

Profit Margin

6.16%

Return On Equity TTM

7.17%

Corcept Therapeutics Incorporated Stock Valuation

Track how Corcept Therapeutics Incorporated P/E has moved over time to understand its valuation trends.

Corcept Therapeutics Incorporated in the last 5 years

  • Overview

  • Trends

Lowest (22.29x)

March 31, 2024

Industry (-9.91x)

May 12, 2026

Today (146.29x)

May 12, 2026

Highest (106.83x)

March 31, 2026

LowHigh

Today’s Price to Earnings Ratio: 146.29x

Corcept Therapeutics Incorporated vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Corcept Therapeutics Incorporated with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Corcept Therapeutics Incorporated image
Corcept Therapeutics Incorporated
BUY$5.5B148.42%146.296.16%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$39.4B113.59%74.1312.55%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$32.2BNA70.468.94%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$109.1B104.61%25.5135.51%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$74.9B40.55%17.4529.65%

Stock Returns calculator for Corcept Therapeutics Incorporated Stock including INR - Dollar returns

The Corcept Therapeutics Incorporated stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Corcept Therapeutics Incorporated investment value today

Current value as on today

₹79,901

Returns

-₹20,099

(-20.1%)

Returns from Corcept Therapeutics Incorporated Stock

-₹29,068 (-29.07%)

Dollar Impact

₹8,969 (+8.97%)

Analyst Recommendation on Corcept Therapeutics Incorporated Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Corcept Therapeutics Incorporated. Average target price of $73.4

Corcept Therapeutics Incorporated Share Price Target

Get share price movements and forecasts by analysts on Corcept Therapeutics Incorporated.

What analysts predicted

30.29%UPSIDE

Target Price

$73.4

Current Price

$51.17

Analyzed by

11 Analysts

Target

$73.40

Corcept Therapeutics Incorporated target price $73.4, a slight upside of 30.29% compared to current price of $51.17. According to 11 analysts rating.

Indian Investors' Interest in Corcept Therapeutics Incorporated Stock

Search interest for Corcept Therapeutics Incorporated Stock has decreased by -29% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-29% versus previous 30 day period

Corcept Therapeutics Incorporated Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
135
146
163
182
181
157
194
207
202
164
Gross Profit
133
144
161
179
178
154
190
203
199
162
Operating Income
31
29
35
46
25
3
26
10
4
-49
EBITDA
32
29
41
47
25
3
27
10
4
-49
Interest Expense
3
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
36
34
41
52
31
9
31
15
9
-44
Income Tax Expense
5
7
6
5
1
-10
-3
-4
-14
-13
Net Income
31
27
35
46
30
20
35
19
24
-31
Net Profit Margin
23.16%
18.91%
21.67%
25.58%
16.71%
13.07%
18.08%
9.47%
12.02%
-18.92%

Corcept Therapeutics Incorporated Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
81
159
251
306
353
365
401
482
675
761
Gross Profit
79
155
246
300
348
360
396
475
664
748
Operating Income
10
52
89
111
128
124
112
107
136
44
EBITDA
10
52
89
113
130
127
115
108
138
46
Interest Expense
2
0
2
5
5
3
3
-
-
-
Depreciation
-
0
0
2
2
3
2
2
1
1
Income Before Tax
8
52
92
116
131
125
116
124
161
66
Income Tax Expense
-
-76
16
22
25
12
14
18
20
-33
Net Income
8
129
75
94
106
112
101
106
139
99
Net Profit Margin
10.01%
81.11%
30.01%
30.73%
29.96%
30.74%
25.24%
22.00%
20.70%
13.09%

Corcept Therapeutics Incorporated Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
27
35
46
30
20
35
19
98
-31
Operating Cash Flow
23
41
73
59
5
43
54
38
-16
Investing Cash Flow
-9
-60
-44
-64
-3
70
14
-11
4
Financing Cash Flow
0
-2
-21
-4
-39
-102
-46
-31
0
Change in Cash
14
-21
8
-9
-37
12
22
-4
-11

Corcept Therapeutics Incorporated Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
129
75
94
106
112
101
106
141
98
Operating Cash Flow
60
115
136
151
167
120
127
198
141
Investing Cash Flow
-73
-90
-117
-119
136
-114
90
-177
69
Financing Cash Flow
-7
-14
-28
12
-302
-17
-148
-28
-220
Change in Cash
-20
10
-10
44
1
-11
69
-7
-7

Global Institutional Holdings in Corcept Therapeutics Incorporated

Funds
Holdings
TD Asset Management Inc
0.93%
HPM Partners LLC
0.7%
BlackRock Inc
11.24%
Geode Capital Management, LLC
2.49%
Citadel Advisors Llc
0.8%
See all

Corcept Therapeutics Incorporated News & Key Events

    Insights on Corcept Therapeutics Incorporated

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 1 month, CORT stock has moved up by 18.2%

    • imgPOSITIVE IMPACT

      Best in 3 Years

      img

      In the last 3 years, CORT has outperformed top 5 stocks with highest market-cap in its industry

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, BeOne Medicines Ltd has given 38.3% return, outperforming this stock by 65.8%

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 2 quarters, 24.28M → -31.20M (in $), with an average decrease of 228.5% per quarter

    • imgNEGATIVE IMPACT

      Revenue Fall

      img

      Revenue is down for the last 3 quarters, 207.63M → 164.90M (in $), with an average decrease of 10.5% per quarter

    About Corcept Therapeutics Incorporated

    Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
    OrganisationCorcept Therapeutics Incorporated
    Headquarters101 Redwood Shores Parkway, Redwood City, CA, United States, 94065
    IndustryBiotechnology
    CEODr. Joseph K. Belanoff M.D.
    E-voting on sharesClick here to vote

    Key Management of Corcept Therapeutics Incorporated

    Name

    Title

    Ms. Amy Flood

    Chief Human Resources & Communications Officer

    Ms. Monica Tellado

    President of Emerging Markets

    Mr. Sean Maduck

    President of Endocrinology

    Mr. Atabak Mokari

    CFO & Treasurer

    Dr. William Guyer Pharm.D.

    Chief Development Officer

    Mr. Gary Charles Robb J.D.

    Chief Business Officer & Secretary

    Mr. Joseph Douglas Lyon

    Chief Technology & Accounting Officer

    Dr. Hazel Hunt Ph.D.

    Chief Scientific Officer

    Mr. Roberto W. Vieira

    President of Oncology

    Dr. Joseph K. Belanoff M.D.

    Co-Founder, President, CEO & Director

    FAQs

    What is Corcept Therapeutics Incorporated share price today?

    Corcept Therapeutics Incorporated share price today is $51.17 as on at the close of the market. Corcept Therapeutics Incorporated share today touched a day high of $51.48 and a low of $50.6.

    What is the 52 week high and 52 week low for Corcept Therapeutics Incorporated share?

    Corcept Therapeutics Incorporated share touched a 52 week high of $91 on and a 52 week low of $28.66 on . Corcept Therapeutics Incorporated stock price today i.e. is closed at $51.17,which is 43.77% down from its 52 week high and 78.54% up from its 52 week low.

    What is Corcept Therapeutics Incorporated's market capitalisation today?

    Corcept Therapeutics Incorporated market capitalisation is $0.01T as on .

    How to invest in Corcept Therapeutics Incorporated Stock (CORT) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Corcept Therapeutics Incorporated on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Corcept Therapeutics Incorporated Shares that will get you 0.0293 shares as per Corcept Therapeutics Incorporated share price of $51.17 per share as on May 13, 2026 at 1:29 am IST.

    What is the minimum amount required to buy Corcept Therapeutics Incorporated Stock (CORT) from India?

    Indian investors can start investing in Corcept Therapeutics Incorporated (CORT) shares with as little as ₹95.618 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹956.18 in Corcept Therapeutics Incorporated stock (as per the Rupee-Dollar exchange rate as on ). Based on Corcept Therapeutics Incorporated share’s latest price of $51.17 as on May 13, 2026 at 1:29 am IST, you will get 0.1954 shares of Corcept Therapeutics Incorporated. Learn more about fractional shares .

    What are the returns that Corcept Therapeutics Incorporated has given to Indian investors in the last 5 years?

    Corcept Therapeutics Incorporated stock has given 148.42% share price returns and 29.61% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?